Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa trial of BI 655130 in palmoplantar pustulosis
2016-004573-40Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Palmoplantar Pustular Psoriasis (PPPP) comparing BI 655130 with Placebo (2 arms). Started Feb 2017; status: completed.
02
Drugs
spesolimab
03
Conditions
Palmoplantar Pustular Psoriasis (PPPP)
Beyond the preview
Go deeper on 2016-004573-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004573-40.